Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab

Leukemia and Lymphoma

Volumn 56, Issue 6, 2015, Pages 1659-1664

  Salmasi, Giselle ^a   Li, Michael ^a   Sivabalasundaram, Vithika ^a   Panzarella, Tony ^a   Tsang, Richard ^a   Kukreti, Vishal ^a   Crump, Michael ^a   Kuruvilla, John ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Antibody based immunotherapy; Chemotherapeutic approaches; Lymphoma and Hodgkin disease

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RISK; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; INCIDENCE; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING; VIRUS INFECTION; CHEMICALLY INDUCED; LUNG DISEASES, INTERSTITIAL; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; INCIDENCE; LUNG DISEASES, INTERSTITIAL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISONE; RETROSPECTIVE STUDIES; RITUXIMAB; VINCRISTINE; YOUNG ADULT;

EID: 84932171706     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.963075     Document Type: Article

References (34)

1. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
2. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-3732.
3. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26: 4579-4586.
4. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
5. Pfreundschuh M, Trumper L, Osterborg A, et al. C HOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabTh era International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
6. Buch M H, Smolen J S, Betteridge N, et al. U pdated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 909-920.
7. Weissert R. P rogressive multifocal leukoencephalopathy. J Neuroimmunol 2011; 231: 73-77.
8. Dunleavy K, Tay K, Wilson WH. Rituximab- Associ. neutropenia. Semin Hematol 2010; 47: 180-186.
9. Burton C, Kaczmarski R, Jan-Mohamed R. I nterstitial pneumonitis related to rituximab therapy. N Engl J Med 2003; 348: 2690-2691; discussion 2690-2691.
10. Kimby E. Tolerability and safety of rituximab (MabTh era). Cancer Treat Rev 2005; 31: 456-473.
11. Bauer PR, Zent CS, Aubry MC, et al. Recurrent fevers, cough, and pulmonary opacities in a middle- Aged man. Chest 2010; 137: 1465-1469.
12. Vulsteke C, Dierickx D, Verbeken E, et al. Rituximab-induced fatal interstitial pneumonitis: case report. Leuk Lymphoma 2010; 51: 546-548.
13. Kemming J L, v an Zeeland R E, Ullmann E F, et al. [ Interstitial pneumonitis as a side effect of rituximab]. Ned Tijdschr Geneeskd 2009; 153: A526.
14. Bitzan M, Anselmo M, Carpineta L. Rituximab (B-cell depleting antibody) associated lung injury (RALI): A pediatric case and systematic review of the literature. Pediatr Pulmonol 2009; 44: 922-934.
15. Kishi J, Nanki T, Watanabe K, et al. A case of rituximab-induced interstitial pneumonitis observed in systemic lupus erythematosus. Rheumatology (Oxford) 2009; 48: 447-448.
16. Kim K M, Kim H C, Jeon K N, et al. R ituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma. Yonsei Med J 2008; 49: 155-158.
17. Heresi GA, Farver CF, Stoller JK. Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature. Respiration 2008; 76: 449-453.
18. Lee Y, Kyung SY, Choi SJ, et al. Two cases of interstitial pneumonitis caused by rituximab therapy. Korean J Intern Med 2006; 21: 183-186.
19. Herishanu Y, Polliack A, Leider-Trejo L, et al. F atal interstitial pneumonitis related to rituximab-containing regimen. Clin Lymphoma Myeloma 2006; 6: 407-409.
20. Ghesquieres H. Severe interstitial pneumonitis following rituximab and bleomycin-containing combination chemotherapy. Ann Oncol 2005; 16: 1399.
21. Hiraga J, Kondoh Y, Taniguchi H, et al. A case of interstitial pneumonia induced by rituximab therapy. Int J Hematol 2005; 81: 169-170.
22. Alexandrescu DT, Dutcher JP, O' Boyle K, et al. Fatal intra- Alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma. Leuk Lymphoma 2004; 45: 2321-2325.
23. Swords R, Power D, Fay M, et al. I nterstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Am J Hematol 2004; 77: 103-104.
24. Jullien V, Perrin C, Peyrade F, et al. [Alveolar hypoxemic interstitial pneumonia related to rituximab therapy]. Rev Mal Respir 2004; 21: 407-410.
25. Liu X, Hong X N, Gu Y J, et al. I nterstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma. Leuk Lymphoma 2008; 49: 1778-1783.
26. Katsuya H, Suzumiya J, Sasaki H, et al. Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. Leuk Lymphoma 2009; 50: 1818-1823.
27. Ennishi D, Terui Y, Yokoyama M, et al. Increased incidence of interstitial pneumonia by CHOP combined with rituximab. Int J Hematol 2008; 87: 393-397.
28. Lim KH, Yoon HI, Kang YA, et al. Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab. Korean J Intern Med 2010; 25: 86-92.
29. Camus P, Kudoh S, Ebina M. I nterstitial lung disease associated with drug therapy. Br J Cancer 2004; 91(Suppl. 2): S18-S23.
30. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99: 754-758.
31. Kim DH, Jung HD, Kim JG, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 2006; 108: 2720-2725.
32. Kim I S, Kim H G, Kim D C, et al. A BCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone chemotherapy. Cancer Sci 2008; 99: 2496-2501.
33. Kamel S, O' Connor S, Lee N, et al. High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma 2010; 51: 797-801.
34. Malik SW, Myers JL, DeRemee RA, et al. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med 1996; 154: 1851-1856.